Amgen Agrees to Pay $24.9 Million for Settlement, Says DOJ
On Tuesday, the Department of Justice (DOJ) announced that the world's largest biotechnology company Amgen has agreed to pay $24.9 million in order to settle allegations against it.
The firm was alleged of providing kickbacks to Omnicare Inc, Kindred Healthcare Inc and PharMerica Corp to persuade them to use its Aranesp anemia drug instead of any other rival drugs. DOJ said that the firm has violated the False Claims Act through paying bribes to the long-term pharmacy providers.
It was learnt that the firm asked the pharmacies to switch the patients on Medicare and Medicaid to Aranesp for anemia treatment. Stuart Delery, the Acting Assistant Attorney General for the Justice Department's Civil Division, said that they will carry out similar pursuits in future is any pharmaceutical company is found guilty of similar charges.
Further, he avowed that the patients deserve proper care that is free from any kind of financial influences. The government has held the biotechnology giant responsible for kickbacks that resulted into performance-based rebates.
The settlement will resolve the lawsuit file under the qui tam. The U. S. Attorney for the District of South Carolina William Nettles said, "By this agreement we are making important strides in holding drug manufacturers accountable for fraudulent and abusive practices".